"Founded by Italian research scientist Dr. Jonathan Fior, Innovative Bioresearch Ltd. is a biotech company bringing disruptive innovation to pharma using blockchain technology to decentralize biomedical research"
Owner and Chief Scientific Officer
Jonathan Fior was born in Los Angeles, USA, in 1982, to Italian parents. Jonathan’s parents moved back to Italy when he was a child, and he completed his education in Italy, a country known for its excellence in the education department. He was always fascinated by science and graduated with a bachelor's degree in medical biotechnology from the University of Milan, Italy. He immediately started working in the field of HIV research, with the goal of bringing innovation to the field. In this regard, he conceived the idea of using irradiated SupT1 cells as a decoy target for HIV-1 to prevent CD4+ T cell depletion as well as to render the virus less cytotoxic. Jonathan explored this approach in an in vitro setting in his 2012 publication, proposing SupT1 cell infusion as a possible cell-based HIV therapy. He then wanted to explore this novel therapeutic approach in an in vivo setting. Given the lack of public funding opportunities in Italy, he decided to start his own research company to support the research through private investor funding and founded Innovative Bioresearch in 2014. Notably, he also personally funded the research with the profits he made working as a stock trader, with great success. He later conducted a groundbreaking pilot study exploring SupT1 cell infusion therapy for HIV in humanized mice and was the first research scientist to believe in the potential of blockchain technology to disrupt pharma, issuing INNBC (InnovativeBioresearchCoin) in 2018. He is also the author of what can be considered the most comprehensive scientific paper on the Salamander regeneration process, how it compares with human healing, and how it can be a model for developing novel regenerative and anticancer therapies. Jonathan Fior believes that "it does not matter whether it’s working on an HIV cure, analyzing the stock market, or fixing cars; a great intellect must be flexible enough to handle any given task". Other than science, one of his biggest passions is JDM sport cars from the 90s, such as Skylines and Supras, which led him to get involved in the JDM tuning community. He also created a webseries, "Skyline Garage," dedicated to the JDM legend car Nissan Skyline GTR and involving mods, JDM car meets, and other car related stuff; Jonathan was even featured on the official Nissan Italy social media accounts to advertise their supercar brand, the Nissan GTR.
Marketing Director and
Enrico Durante is an experienced marketer specialized in Management, Growth Hacking, Business Development, Marketing, and blockchain knowledge. One of his strongest qualities is that he always puts himself in the client's shoes. Every project has its own target audience with their own needs, expectations, tastes, etc. When starting a project, he always takes his time to carefully plan, research, and experiment before kicking off with the final strategies. He also operates locally to provide direct assistance to Italian commercial activities using INNBC as a means of payment; you can see him in action in this video filmed at one of the largest construction companies in Messina, Italy, accepting INNBC as a means of payment.
Chief Legal Officer
Michael is our strong and hard working community manager, doing his best to also moderate our very active Telegram group (https://t.me/innovativebioresearch), which can get very wild sometimes!
Alessandro Gatti is a legal expert and he ensures that everything we do is in accordance with the law.
HOW WE OPERATE
For research projects, Jonathan Fior works as the PI (principal investigator), conceiving the experiments and writing the experiment protocol. The work is then assigned to a Contract Research Organization (CRO), which physically performs the experiments. Jonathan Fior then supervises all aspects related to the research, communicating closely with the CRO. Once the experiments are completed, he analyzes the results and writes a scientific paper, which is published in a peer-reviewed scientific journal. This means that although our team is not large, we actually have companies with 100+ people working for us. For example, for our HIV study in humanized mice, we used a state-of-the-art CRO company such as AXENIS, a spin-off of the Institut Pasteur (Paris, France), which has now been acquired by Genoway. This way, we can keep a small, yet strong and great, team. We only publish in open-access scientific journals because we believe in free information and don’t want our data to be hidden behind a paywall.